1. Home
  2. APPN vs GLPG Comparison

APPN vs GLPG Comparison

Compare APPN & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Appian Corporation

APPN

Appian Corporation

HOLD

Current Price

$23.47

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$27.73

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPN
GLPG
Founded
1999
1999
Country
United States
Belgium
Employees
N/A
452
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.9B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
APPN
GLPG
Price
$23.47
$27.73
Analyst Decision
Hold
Buy
Analyst Count
5
2
Target Price
$29.80
$36.50
AVG Volume (30 Days)
927.0K
118.1K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
N/A
EPS
0.02
N/A
Revenue
$226,743,000.00
N/A
Revenue This Year
$13.79
N/A
Revenue Next Year
$10.56
N/A
P/E Ratio
$1,156.50
N/A
Revenue Growth
28.29
N/A
52 Week Low
$19.79
$24.74
52 Week High
$46.06
$37.78

Technical Indicators

Market Signals
Indicator
APPN
GLPG
Relative Strength Index (RSI) 56.32 36.68
Support Level $22.39 $27.73
Resistance Level $25.22 $34.04
Average True Range (ATR) 1.24 0.56
MACD 0.35 0.08
Stochastic Oscillator 79.10 26.20

Price Performance

Historical Comparison
APPN
GLPG

About APPN Appian Corporation

Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its Domestic operations, and also has its presence Internationally.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: